Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on October 17, 2025
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab …
Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging leader in botanical-based biotechnology, today announced its strategic initiative to redesign its corporate website and develop a dedicated Investor Relations (IR) …
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, …
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced the launch of WeightWatchers RxFlexFund™, a first-of-its-kind …
Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
24/7 Market News- Kraig Labs Spider Silk Poised to Lead the Sustainable Textile Revolution
DENVER, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that, as the fashion industry confronts mounting pressure to overhaul its wasteful …
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also been addressed In …
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and …
Vystar’s Vytex® Cloud Bed-in-a-Box Available for Sale
Luxuriously soft supportive com fort, resilience and breathability Thicker mattress and the ultimate plush covering 6 sizes, 3 levels of softness World’s purest, naturally anti-microbial, odor-free and virtually allergen free latex Made of globally paten …
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-up Immune activation observed in all patients with 81% of EVX-01’s vaccine …
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating …
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee for …
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular …
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a Phase 3 study in China sponsored by …
Zus Health Helps Value-Based Care Organizations Capture Accurate Risk with Intuitive, Evidence-Based Workflows
BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Zus Health, the always-on data platform that unifies every patient record into a single, comprehensive view, today announced new capabilities for accurately capturing a patient’s burden of illness. Zus’s new risk …
SRx Health Solutions Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
TAMPA, Fla., Oct. 17, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) that the Company was not in compliance with the …
Anthem Blue Cross and Blue Shield and Sauk Prairie Healthcare to Strengthen Health Outcomes in Wisconsin
MADISON, Wisc., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Anthem Blue Cross and Blue Shield in Wisconsin (Anthem) and Sauk Prairie Healthcare are pleased to announce that Sauk Prairie Healthcare is rejoining Anthem’s network effective January 1, 2026. This renewal …
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort – Favorable …